Cilostazol

Overview

Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.

Indication

Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).

Associated Conditions

Intermittent Claudication

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage	2025/08/28	NCT07144956	Not Applicable	Not yet recruiting	Centre Hospitalier St Anne
CiLostAzol for pReventIon of Recurrent sTroke in Africa	2025/04/09	NCT06919835	Phase 3	Not yet recruiting	Northern California Institute of Research and Education
Assess the Safety and Effectiveness of Once Daily PMR Compared to Twice Daily Pletaal® in Patients With Intermittent Claudication	2025/03/20	NCT06886620	Phase 3	Terminated	Genovate Biotechnology Co., Ltd.,
The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis	2025/01/03	NCT06757764	Phase 4	Recruiting	Asan Medical Center
Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases	2024/12/04	NCT06715007	N/A	Recruiting	The First Affiliated Hospital with Nanjing Medical University
Cilostazol in Parkinson's Disease	2024/09/25	NCT06612593	Phase 2	Not yet recruiting	Ain Shams University
Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA	2024/09/19	NCT06591377	Phase 3	Recruiting	Kafrelsheikh University
Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA	2024/09/11	NCT06591390	Phase 3	Recruiting	Kafrelsheikh University
Combining Aspirin With Cilostazol or Clopidogrel in Minor Stroke or TIA	2024/09/11	NCT06591299	Phase 3	Recruiting	Kafrelsheikh University
Combining Aspirin With Cilostazol or Clopidogrel in Large-vessel Minor Stroke or TIA	2024/09/11	NCT06591351	Phase 3	Recruiting	Kafrelsheikh University

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Cilostazol	REMEDYREPACK INC.	70518-2208	ORAL	50 mg in 1 1	2/27/2024
Cilostazol	A-S Medication Solutions	50090-5329	ORAL	50 mg in 1 1	7/26/2022
Cilostazol	Teva Pharmaceuticals USA, Inc.	0093-2064	ORAL	100 mg in 1 1	7/31/2022
Cilostazol	Aphena Pharma Solutions - Tennessee, LLC	71610-037	ORAL	100 mg in 1 1	2/2/2018
cilostazol	REMEDYREPACK INC.	70518-2714	ORAL	100 mg in 1 1	3/5/2024
cilostazol	Apotex Corp.	60505-2522	ORAL	100 mg in 1 1	12/13/2023
cilostazol	AvKARE	42291-453	ORAL	100 mg in 1 1	1/9/2024
Cilostazol	Carilion Materials Management	68151-4123	ORAL	100 mg in 1 1	7/6/2016
Cilostazol	Teva Pharmaceuticals USA, Inc.	0093-2065	ORAL	50 mg in 1 1	7/31/2022
Cilostazol	Slate Run Pharmaceuticals, LLC	70436-156	ORAL	50 mg in 1 1	4/16/2021

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
EKISTOL 50 mg COMPRIMIDOS	Lacer S.A.	70126	COMPRIMIDO	Diagnóstico Hospitalario	Commercialized
CILOSTAZOL STADA 100 MG COMPRIMIDOS EFG	Laboratorio Stada S.L.	78181	COMPRIMIDO	Diagnóstico Hospitalario	Commercialized
CILOSTAZOL CINFA 100 MG COMPRIMIDOS EFG	Laboratorios Cinfa S.A.	78222	COMPRIMIDO	Diagnóstico Hospitalario	Commercialized
CILOSTAZOL NORMON 100 MG COMPRIMIDOS EFG	Laboratorios Normon S.A.	78146	COMPRIMIDO	Diagnóstico Hospitalario	Commercialized
CILOSTAZOL PHARMAGENUS 100 MG COMPRIMIDOS EFG	Aristo Pharma Iberia S.L.	78227	COMPRIMIDO	Diagnóstico Hospitalario	Not Commercialized
CILOSTAZOL TROMBICOR 100 MG COMPRIMIDOS EFG	Grupo J Uriach S.L.	81267	COMPRIMIDO	Diagnóstico Hospitalario	Not Commercialized
CILOSTAZOL ARISTO 50 MG COMPRIMIDOS EFG	Aristo Pharma Iberia S.L.	78833	COMPRIMIDO	Diagnóstico Hospitalario	Commercialized
CILOSTAZOL PENSA 100 MG COMPRIMIDOS EFG	Towa Pharmaceutical S.A.	78177	COMPRIMIDO	Diagnóstico Hospitalario	Commercialized
CILOSTAZOL KERN PHARMA 100 MG COMPRIMIDOS EFG	Kern Pharma S.L.	78148	COMPRIMIDO	Diagnóstico Hospitalario	Commercialized
EKISTOL 100 mg COMPRIMIDOS	Lacer S.A.	70125	COMPRIMIDO	Diagnóstico Hospitalario	Commercialized

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Heart Drug Cilostazol Shows Promise for Treating Growth Disorders in Preclinical Study

2 months ago

Researchers discovered that phosphodiesterase 3 (PDE3) inhibitors, currently used for heart disease and thrombosis, can stimulate bone growth by enhancing calcium influx into bone cells.

Sotatercept Shows Promise in Pulmonary Hypertension, Obicetrapib/Ezetimibe Lowers LDL-C

9 months ago

• Merck's sotatercept (Winrevair) met the primary endpoint in the Phase 3 ZENITH trial, demonstrating potential in treating pulmonary arterial hypertension. • A fixed-dose combination of obicetrapib and ezetimibe nearly halved LDL cholesterol in statin-resistant patients, according to NewAmsterdam Pharma. • Real-world data indicates improved outcomes with the Sapien 3 Ultra Resilia TAVR valve compared to older models, Edwards Lifesciences reported.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access